Divi's Laboratories Limited share price
NSE: DIVISLAB · BSE: 532488 · ISIN INE361B01024
Key numbers
- Market cap
- ₹ 2,55,368 Cr
- Current price
- ₹ 9,619.50
- 52-week high / low
- ₹ 9,740 / 5,637
- Stock P/E
- 87.1
- Book value
- ₹ 631.4
- Dividend yield
- 0.31%
- ROCE
- 21.5%
- ROE
- 16.2%
- Debt to equity
- 0.00
- Sales growth (3 yrs)
- 11.0%
- Profit growth (3 yrs)
- 12.1%
- 1-year return
- 59.0%
About Divi's Laboratories Limited
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 2,585 | 2,410 | 2,604 | 2,831 | 3,080 |
| Operating profit | 886 | 729 | 890 | 934 | 1,255 |
| Net profit | 662 | 545 | 583 | 751 | 902 |
| EPS (₹) | 24.93 | 20.49 | 21.98 | 28.31 | 33.95 |
Concall summary (2026-08-06)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- I welcome you to the earnings call of the Divi's Laboratories Limited for the first quarter of FY27.
- These estimates reflect management's current expectations of the future performance of the Company.
Growth & demand
- On a constant currency basis, the standalone revenue recorded a growth of 10% during the quarter.
- Just on the second question on Custom Synthesis , strong growth this quarter, 60% of total revenue.
Margins & costs
- Raw material availability remained largely stable, although input cost trends continue to vary across categories.
- While prices of certain raw materials moderated during the quarter, solvent costs remain elevated for a significant part of the period.
Capex & expansion
- Likewise, the three major capex programmes are nearing completion and validations are going on.
- Alongside capacity expansion in both solid-phase and liquid-phase peptide synthesis, we continue to strengthen the process development, analytical and manufacturing capabilities required for increasingly complex peptide chemistry.
Balance sheet & cash
- As of the end of the quarter, cash and cash equivalents stood at ₹3,611 crores, trade receivables were ₹3,056 crores and inventory stood at ₹4,413 crores.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.